Association between serum biomarkers  CEA  and  LDH  and response in advanced non‐small cell lung cancer patients treated with platinum‐based chemotherapy

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background

In addition to radiological evaluation, biomarkers may be useful in providing early information on the response to treatment, and supporting clinical decision‐making. The objective of this study was to investigate carcinoembryonic antigen (CEA) and lactate dehydrogenase (LDH) as biomarkers for early assessment of response in patients with advanced non‐small cell lung cancer (NSCLC) treated with platinum‐based chemotherapy.

Methods

A retrospective follow‐up study was conducted from 2012 to 2017 among 593 consecutive patients with advanced NSCLC treated with first‐line platinum‐based chemotherapy in a large teaching hospital in the Netherlands. Pretreatment biomarker levels and changes from pretreatment levels were studied for association with radiologic response (partial response [PR] or complete response [CR], according to RECIST 1.1) using multivariate logistic regression, and with overall survival using COX proportional hazard modeling. Patient and disease characteristics such as age and disease stage were taken into account as potential confounding factors.

Results

Decreases in CEA and LDH (≥ 20%), particularly early in treatment, were significantly associated with better radiological response. Increases in these biomarkers (≥ 20%) and high pretreatment LDH levels (≥ 247 U/L) were significantly associated with lower overall survival.

Conclusions

Our results support determination of CEA and LDH levels for earlier assessment of response to platinum‐based chemotherapy in patients with advanced NSCLC. Hence, routine determination and evaluation of CEA and LDH levels, prior to each cycle of platinum‐based chemotherapy in advanced NSCLC, should be considered as part of daily clinical practice.

Key points

Significant findings of the study

Serum biomarkers in monitoring of treatment in advanced NSCLC would be useful.
CEA and LDH decrease (≥ 20%) is favorable for achieving radiological response.
High LDH levels and CEA/LDH increase (≥ 20%) is associated with reduced survival.

What this study adds

Monitoring of CEA seems to be particularly relevant in early stage of treatment.
CEA and LDH determination should be considered as part of daily clinical practice.

Related collections

Most cited references 20

Record: found
Abstract: found
Article: not found

REporting recommendations for tumour MARKer prognostic studies (REMARK)

L M McShane, D Altman, W Sauerbrei … (2005)

Despite years of research and hundreds of reports on tumour markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often initially reported studies of a marker show great promise, but subsequent studies on the same or related markers yield inconsistent conclusions or stand in direct contradiction to the promising results. It is imperative that we attempt to understand the reasons that multiple studies of the same marker lead to differing conclusions. A variety of methodological problems have been cited to explain these discrepancies. Unfortunately, many tumour marker studies have not been reported in a rigorous fashion, and published articles often lack sufficient information to allow adequate assessment of the quality of the study or the generalisability of the study results. The development of guidelines for the reporting of tumour marker studies was a major recommendation of the US National Cancer Institute and the European Organisation for Research and Treatment of Cancer (NCI-EORTC) First International Meeting on Cancer Diagnostics in 2000. Similar to the successful CONSORT initiative for randomised trials and the STARD statement for diagnostic studies, we suggest guidelines to provide relevant information about the study design, preplanned hypotheses, patient and specimen characteristics, assay methods, and statistical analysis methods. In addition, the guidelines suggest helpful presentations of data and important elements to include in discussions. The goal of these guidelines is to encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.

0 comments Cited 533 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: not found
Article: not found

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

D Planchard, S Popat, K Kerr … (2019)

0 comments Cited 113 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Treatment advances in small cell lung cancer (SCLC).

Daniel Morgensztern, Saiama N Waqar (2017)

Small cell lung cancer (SCLC) is an aggressive tumor characterized by rapid doubling time and high propensity for early development of disseminated disease. Although most patients respond to initial therapy with a platinum doublet, the majority of those with limited stage and virtually all patients with metastatic disease eventually develop tumor progression for which there are limited treatment options. There have been no recent changes in the treatment of SCLC, with platinum plus etoposide and topotecan as the standard first-line and second-line respectively, neither showing survival benefit over the combination of cyclophosphamide, doxorubicin and vincristine, which was developed in the 1970s. More recently, a new understanding of the biology of SCLC has led to the development of novel drugs, of which the most promising are the immune checkpoint inhibitors and the antibody drug conjugate rovalpituzumab tesirine.

0 comments Cited 82 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Corine de Jong:

ORCID: https://orcid.org/0000-0003-0746-5057

d.c.dejong-15@umcutrecht.nl

Vera H.M. Deneer:

ORCID: https://orcid.org/0000-0002-8564-4424

v.h.m.deneer@umcutrecht.nl

Journal

Journal ID (nlm-ta): Thorac Cancer

Journal ID (iso-abbrev): Thorac Cancer

Journal ID (doi): 10.1111/(ISSN)1759-7714

Journal ID (publisher-id): TCA

Title: Thoracic Cancer

Publisher: John Wiley & Sons Australia, Ltd (Melbourne )

ISSN (Print): 1759-7706

ISSN (Electronic): 1759-7714

Publication date (Electronic): 07 May 2020

Publication date (Print): July 2020

Volume: 11

Issue: 7 ( doiID: 10.1111/tca.v11.7 )

Pages: 1790-1800

Affiliations

[ ¹ ] Department of Clinical Pharmacy St. Antonius Hospital Nieuwegein/Utrecht The Netherlands

[ ² ] Department of Clinical Pharmacy University Medical Center Utrecht Utrecht The Netherlands

[ ³ ] Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science Utrecht University Utrecht The Netherlands

[ ⁴ ] Department of Epidemiology and Statistics St. Antonius Hospital Nieuwegein/Utrecht The Netherlands

[ ⁵ ] Department of Clinical Chemistry St. Antonius Hospital Nieuwegein/Utrecht The Netherlands

[ ⁶ ] Department of Pulmonology Meander Medical Center Amersfoort The Netherlands

Author notes

[*] [* ] Correspondence

Vera H.M. Deneer, PharmD, PhD, Department of Clinical Pharmacy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.

Tel: +31 8875 5721

Email: v.h.m.deneer@ 123456umcutrecht.nl

Author information

Corine de Jong https://orcid.org/0000-0003-0746-5057

Vera H.M. Deneer https://orcid.org/0000-0002-8564-4424

Johannes C. Kelder https://orcid.org/0000-0001-9084-8192

Toine C.G. Egberts https://orcid.org/0000-0003-1758-7779

Article

Publisher ID: TCA13449

DOI: 10.1111/1759-7714.13449

PMC ID: 7327701

PubMed ID: 32383328

SO-VID: 15f5f9da-b871-4812-a74e-79992d0e4c1f

License:

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

History

Date received : 19 January 2020

Date revision received : 03 April 2020

Date accepted : 04 April 2020

Page count

Figures: 1, Tables: 5, Pages: 11, Words: 6102

Custom metadata

source-schema-version-number 2.0

cover-date July, 2020

details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.5 mode:remove_FC converted:01.07.2020

Keywords: non‐small cell lung cancer (nsclc),small cell lung cancer (sclc),carcinoembryonic antigen (cea),lactate dehydrogenase (ldh),noninvasive quantification of tumor biomarkers

Data availability:

Keywords: non‐small cell lung cancer (nsclc), small cell lung cancer (sclc), carcinoembryonic antigen (cea), lactate dehydrogenase (ldh), noninvasive quantification of tumor biomarkers

Association between serum biomarkers CEA and LDH and response in advanced non‐small cell lung cancer patients treated with platinum‐based chemotherapy

Read this article at

Abstract

Background

Methods

Results

Conclusions

Key points

Significant findings of the study

What this study adds

Related collections

Journal of Circulating Biomarkers

Most cited references 20

REporting recommendations for tumour MARKer prognostic studies (REMARK)

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Treatment advances in small cell lung cancer (SCLC).

Author and article information

Contributors

Journal

Affiliations

Author notes

Author information

Article

History

Page count

Categories

Custom metadata

Comments

Comment on this article

Similar content 204

Cited by 16

Most referenced authors 511